NCT04321668View on ClinicalTrials.gov

Innovative Tool to Analyse Synovial Fluid of Patients With Knee Ostearthritis After IA Injection of Synvisc-one®

NACompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

February 12, 2020

Primary Completion Date

October 1, 2021

Study Completion Date

February 15, 2022

Conditions
Knee OsteoarthritisIntra-Articular Injection
Interventions
DEVICE

Synvisc-One

SYNVISC-ONE® (Hylan G-F 20), 10 mL single-injection viscosupplement Status : CE marked (CE 0086) class III Medical Device The IP is used according to its usual dosage, administration and indication

Trial Locations (3)

1150

Centre Medical Chant d'Oiseau, Woluwe-Saint-Pierre - Sint-Pieters-Woluwe

1160

Hopital Delta, CHIREC, Auderghem

Unknown

Cliniques Universitaires Saint Luc - UCL, Woluwe-Saint-Pierre - Sint-Pieters-Woluwe

Sponsors

Collaborators (1)

Artialis
All Listed Sponsors
collaborator

Artialis

INDUSTRY

lead

Pulsalys

INDUSTRY

NCT04321668 - Innovative Tool to Analyse Synovial Fluid of Patients With Knee Ostearthritis After IA Injection of Synvisc-one® | Biotech Hunter | Biotech Hunter